Eli Lilly and logo

Eli Lilly and

LLY | NYSE
Chart Builder DCF Calculator
$1,165.83
+$12.90 (+1.12%)
Sep 21, 2026, 11:05 AM ET · Market open

Company Profile

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Key Executives

Name Position
David A. Ricks Chairman, Chief Executive Officer & President
Eric Dozier Executive Vice President & Chief People Officer
Lucas E. Montarce Executive Vice President & Chief Financial Officer
Anat Hakim Executive Vice President, General Counsel & Secretary
Daniel Skovronsky Chief Scientific & Product Officer and President of Lilly Research Laboratories
Diogo Rau Executive VP and Chief Information & Digital Officer
Donald A. Zakrowski Senior Vice President of Finance & Chief Accounting Officer
Ilya Yuffa Executive VP and President of Lilly USA & Global Customer Capabilities
Jacob S. Van Naarden Executive VP, President of Lilly Oncology & Head of Corporate Business Development
Michael Czapar Senior Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Sep 04, 2026 3/A [Amend] Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 11, 2026 4 Filing
Aug 10, 2026 4 Filing
View All SEC Filings
Eli Lilly and
Eli Lilly and logo
Country United States
IPO Date May 31, 1972
Industry Drug Manufacturers - General
Sector Healthcare
Employees 50,000
CEO David A. Ricks

Contact Details

Lilly Corporate Center Indianapolis, Indiana 46285 United States

Stock Details

Ticker Symbol LLY
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000059478
CUSIP Number 532457108
ISIN Number US5324571083
SIC Code 2834

© 2026 bestshares.com. All rights reserved.